SCHEMBL1421130

SCHEMBL1421130

COc1ccc(/C=C2\SC(=S)N(c3ccc(F)nc3)C2=O)cc1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.61
KMT2A Q03164 7/20 0.61
CACNA1B Q00975 1/20 0.61
APBA1 Q02410 1/20 0.61
GRK6 P43250 1/20 0.61
PDE4B Q07343 2/20 0.58
MAPT P10636 5/20 0.56
LMNA P02545 2/20 0.56
ALDH1A1 P00352 1/20 0.56
HSD17B3 P37058 1/20 0.55
HSPD1 P10809 1/20 0.54
HSPE1 P61604 1/20 0.54
ATM Q13315 1/20 0.54
POLB P06746 3/20 0.50
IDE P14735 2/20 0.50
HTT P42858 1/20 0.50
S1PR1 P21453 1/20 0.50
S1PR3 Q99500 1/20 0.50
OPRK1 P41145 2/20 0.48
PSMD14 O00487 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1421134 1.00 MEN1 (0.61) MEN1KMT2ACACNA1BAPBA1GRK6
SCHEMBL1421133 1.00 MEN1 (0.61) MEN1KMT2ACACNA1BAPBA1GRK6
SCHEMBL1421138 0.85 MEN1 (0.61) MEN1KMT2ACACNA1BAPBA1GRK6
SCHEMBL1421135 0.85 MEN1 (0.61) MEN1KMT2ACACNA1BAPBA1GRK6
SCHEMBL1421493 0.83 KMT2A (0.85) MEN1KMT2ACACNA1BAPBA1GRK6
SCHEMBL1421494 0.83 KMT2A (0.85) MEN1KMT2ACACNA1BAPBA1GRK6
SCHEMBL1421491 0.83 KMT2A (0.85) MEN1KMT2ACACNA1BAPBA1GRK6
SCHEMBL1421361 0.80 PDE4B (0.60) MEN1KMT2ACACNA1BAPBA1GRK6
SCHEMBL1421362 0.80 PDE4B (0.60) MEN1KMT2ACACNA1BAPBA1GRK6
SCHEMBL1421357 0.80 PDE4B (0.60) MEN1KMT2ACACNA1BAPBA1GRK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098323-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION MICROBIOTIX, INC. (US) 2011-04-28 US claimed
EP-2296476-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION Microbiotix, Inc. (US) 2011-03-23 EP claimed
WO-2009142720-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION MICROBIOTIX, INC. (US) 2009-11-26 WO claimed
US-20110098323-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION MICROBIOTIX, INC. (US) 2011-04-28 US disclosed
EP-2296476-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION Microbiotix, Inc. (US) 2011-03-23 EP disclosed
WO-2009142720-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION MICROBIOTIX, INC. (US) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098323-A1 INHIBITORS OF BACTERIAL BIOFILM FORMATION BLVRB, TFPI, FOSB MEN1 4836/4885KMT2A 3896/4885CACNA1B 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.